Nexigen appoints Dr. Jörg Vollmer as CEO
(Thomson Reuters ONE) -
Nexigen GmbH /
Nexigen appoints Dr. Jörg Vollmer as CEO
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Cologne, 19 October 2011. Nexigen GmbH, a biopharmaceutical company developing
therapeutic peptides to fight cancer, announced the appointment of Dr. Jörg
Vollmer as CEO and member of the management board of the company. Dr. Vollmer is
the former Managing Director of Coley Pharmaceutical GmbH, a subsidiary of
Pfizer Inc., and brings in experience from both the biotech and pharma
industries. The acquisition of Dr. Vollmer will strongly support the current
growth phase of the company to become a leading drug developer for innovative
therapeutics in cancer.
Between 2008 and 2011 Dr. Vollmer was Managing Director of Coley Pharmaceutical
GmbH, a subsidiary of Pfizer Inc. Coley Pharmaceutical was then part of Pfizer
Research. As part of Pfizer's Oligonucleotide Therapeutics Unit (OTU), Dr.
Vollmer concentrated on the development of gene-silencing nucleic acid
therapeutics such as siRNA and antisense. This field perfectly matches Nexigen's
positioning as a developer of innovative drugs targeting previously inaccessible
disease mechanisms.
Before 2008, Dr. Vollmer held several senior management positions at Coley
Pharmaceutical Group, latest as Vice President Discovery & Development. In this
role he was responsible for the identification and evaluation of novel product
candidates and new research and application areas. Coley Pharmaceutical was a
pioneer in developing a class of drug candidates called TLR Therapeutics,
oligonucleotide drugs to modulate the immune system. Jörg Vollmer holds a degree
in Biology from the University of Freiburg and a PhD in Immunology from the Max-
Planck-Institute of Immunobiology.
Dr. Vollmer is Member of the Board of the biotechnology network BioRiver e.V. in
North Rhine-Westphalia.
"With his broad experience in discovery & development and from the
pharmaceutical industry, Dr. Vollmer is the ideal candidate for this key
position within our company", said Dr. Hanjo Hennemann, CSO and founder of
Nexigen.
"Nexigen's proprietary peptide platform has the potential to enable successful
development of peptide modulators targeting disease mechanisms which
traditionally have not been accessible for drug discovery. I am excited to work
with Hanjo Hennemann and his team and to contribute to the future success of
Nexigen", comments Dr. Jörg Vollmer.
The appointment of Dr. Vollmer as CEO of Nexigen strengthens the company in its
process of becoming one of the leading drug developers for innovative
therapeutics with novel and potentially superior properties.
About Nexigen GmbH
Nexigen GmbH was founded in August 2007, obtained its first capital in 2008 und
develops peptide therapeutics with novel modes of action for the treatment of
cancer. The company aims at so far inaccessible proteins, which are crucially
involved in the onset and progression of tumors. Nexigen relies on proprietary
and innovative peptide screening technologies in living cells. This allows for
the time and cost-efficient access to drug discovery. Currently Nexigen GmbH
cooperates with various biotech companies and successfully completed projects
with leading pharmaceutical companies
Please contact us for further information!
Daniela Thiebes
Nexigen GmbH
+49 (221) 33 77 72-00
thiebes(at)nexigen.de
--- End of Message ---
Nexigen GmbH
Ludwig-Erhard-Allee 2 Bonn Germany
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Nexigen GmbH via Thomson Reuters ONE
[HUG#1556070]
Datum: 19.10.2011 - 13:55 Uhr
Sprache: Deutsch
News-ID 77956
Anzahl Zeichen: 4484
contact information:
Town:
Bonn
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 188 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Nexigen appoints Dr. Jörg Vollmer as CEO"
steht unter der journalistisch-redaktionellen Verantwortung von
Nexigen GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
